SCHEMBL6710587

SCHEMBL6710587

Cc1cc(NC(=O)c2c(C)noc2C)ccc1C(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.64
KDR P35968 2/20 0.64
GFER P55789 1/20 0.56
ALDH1A1 P00352 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
CRACR2A Q9BSW2 1/20 0.53
GAA P10253 2/20 0.52
TP53 P04637 1/20 0.52
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
AGTR1 P30556 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALOX15 P16050 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
EPAS1 Q99814 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8376768 0.87 FLT1 (0.53) FLT1KDRALDH1A1GAAKDM4E
SCHEMBL8376785 0.84 FLT1 (0.51) FLT1KDRALDH1A1KDM4EMAPT
SCHEMBL7076714 0.83 GFER (0.60) GFERALDH1A1L3MBTL1GAATP53
SCHEMBL9422978 0.82 HTT (0.66) FLT1KDRALDH1A1TP53KDM4E
SCHEMBL6707794 0.82 GFER (0.65) FLT1KDRGFERALDH1A1L3MBTL1
SCHEMBL16363167 0.82 GFER (0.53) FLT1KDRGFERALDH1A1L3MBTL1
SCHEMBL1826603 0.81 GFER (0.52) FLT1KDRGFERALDH1A1CRACR2A
SCHEMBL6709120 0.81 FLT1 (0.57) FLT1KDRALDH1A1KDM4EMAPT
SCHEMBL6707284 0.78 FLT1 (0.51) FLT1KDRTP53MAPTNPSR1
SCHEMBL9182578 0.78 RAB9A (0.69) FLT1KDRCRACR2ATP53NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC FLT1 727/4885KDR 633/4885GFER 3800/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC FLT1 727/4885KDR 633/4885GFER 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.